Clinical Trials Directory

Trials / Completed

CompletedNCT04629430

Effects of Prebiotics on Gut Microbiome in Patients Undergoing HSCT

Effects of Prebiotics on Gut Microbiome in Patients Undergoing Stem Cell Transplants

Status
Completed
Phase
N/A
Study type
Interventional
Enrollment
40 (actual)
Sponsor
University of Virginia · Academic / Other
Sex
All
Age
18 Years
Healthy volunteers
Not accepted

Summary

The purpose of this study is to see whether hematopoietic stem cell transplant (HSCT) patients can consistently eat a diet rich in prebiotics. This type of diet may be helpful in maintaining diversity in the gastrointestinal (GI) system and therefore potentially decreasing risk of other GI problems.

Detailed description

Maintaining gastrointestinal (GI) microbiome diversity has been shown to improve treatment related mortality in HSCT patients. Interventions to improve GI microbial diversity could be beneficial to this patient population. Diets rich in prebiotics have been shown to increase gut microbial diversity and improve symptoms in other gastrointestinal diseases. Prebiotics are non-digestible carbohydrates that promote growth of commensal organisms in the gut by providing nutrition. Some examples are brown rice, green apples, and tomatoes. Our theory is that consuming a diet rich in prebiotics pre- and during the first 100 days following HSCT will help to reduce acute graft versus host disease (aGVHD) overall, and specifically acute GI GVHD, and clostridium difficile (C.Diff). Participants will be encouraged to eat at least 2 servings of a prebiotic-rich food from time of admission for HSCT through 100 days following HSCT and will be clinically monitored, including for acute GVHD, acute GI GVHD and C.Diff. Stool samples will be collected from all participants about once every 4 weeks.

Conditions

Interventions

TypeNameDescription
OTHERPre-biotic foods/drinks2 servings per day

Timeline

Start date
2021-02-19
Primary completion
2022-10-28
Completion
2022-10-28
First posted
2020-11-16
Last updated
2023-01-04

Locations

1 site across 1 country: United States

Source: ClinicalTrials.gov record NCT04629430. Inclusion in this directory is not an endorsement.